ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

The ATHENA Study: 12 Months Safety and Efficacy Data from Everolimus Combined with Tacrolimus or Cyclosporine Compared to a Standard Tacrolimus-Mycophenolate Regimen in De Novo Kidney Transplant Patients

B. Suwelack,1 C. Sommerer,1 D. Dragun,1 O. Witzke,1 C. Hugo,1 N. Kamar,2 P. Merville,2 A. Hauser,1 P. Schenker,1 M. Junge,3 B. Nashan,1 F. Thaiss.1

1Athena Study Group, Germany
2Athena Study Group, France
3Novartis, Pharma, Germany.

Meeting: 2018 American Transplant Congress

Abstract number: 37

Keywords: Efficacy, Immunosuppression, Kidney transplantation

Session Information

Date: Sunday, June 3, 2018

Session Name: Concurrent Session: Kidney Immunosuppression: mTORi Based Regimens

Session Time: 2:30pm-4:00pm

 Presentation Time: 3:18pm-3:30pm

Location: Room 6A

Related Abstracts
  • Allograft Function after 12 Months with Everolimus Plus Either Tacrolimus or Cyclosporine Compared to a Standard Regimen of Tacrolimus with MPA in De Novo Renal Transplant Recipients: The ATHENA Study
  • Significant Anti-CMV/BKV Effect of a Modern Everolimus-Based Regimen Comparted to a Standard Tacrolimus-MPA Regimen in De Novo Kidney Transplant Recipients: ATHENA 12 Months Data on Infections

The ATHENA study was set up to compare efficacy and safety of everolimus [EVR] combined with tacrolimus [TAC] or cyclosporine A [CyA] vs. a mycophenolic acid [MPA] plus TAC standard regimen in de novo kidney transplant [KTx] recipients.

Methods: In this 12 months [M] prospective, open-label, multi-center study, 612 patients [pts] were randomized 1:1:1 at time of Tx to either EVR (3-8ng/ml M1-M12) +TAC (4-8ng/ml M1-M3; 3-5ng/ml M3-M12), or EVR (3-8ng/ml M1-M12) +CyA (75-125ng/ml M1-M3; 50-100ng/ml M3-M12) or TAC (4-8ng/ml M1-M3; 3-5ng/ml M3-M12) +MPA; all with steroids. Here we report M12 efficacy and safety data from 208 EVR+TAC, 199 EVR+CyA and 205 TAC+MPA treated pts.

Results: Treated BPAR occurred in 6.7% of EVR+TAC vs 17.6% of EVR+CyA and 3.9% of TAC+MPA pts. Most events were graded mild (BANFF IA: 1.9% vs 9% vs 1.5%), only few as BANFF IIB/III (1.5% vs 2% vs 0.5%, respectively). Death occurred in 5 EVR+TAC pts, 5 EVR+CyA and 6 TAC+MPA pts. Incidence of graft loss was: 4.8% (10 pts) in EVR+TAC vs 6.5% (13pts) in EVR+CyA and 2.9% (6pts) in TAC+MPA group, including 5 primary non-functioning grafts in each EVR-group and 1 in TAC+MPA group. Safety was comparable with incidence of AEs leading to study drug discontinuation or dose adjustment/interruption [d/p] in 56.7% pts of EVR+TAC, 55.5% pts of EVR+CyA vs 61.3% pts in TAC+MPA arm. Main reasons for d/p of study drug were infections (as reason for d/p: 15.2%EVR+TAC, 10.1%EVR+CyA, 31.3%TAC+MPA) and leukopenia (as reason for d/p: 1.9%EVR+TAC, 3.0%EVR+CyA vs.10.8%TAC+MPA). There were no differences on wound healing/complications with corresponding total incidences of 41.9% in EVR+TAC, 38.9% in EVR+CyA and 43.2% in TAC+MPA group. There was no difference in proteinuria and incidence of nephrotic proteinuria was 1.3% in EVR+TAC vs 0.7% in EVR+CyA and 3.7% in TAC+MPA treated patients.

Conclusion: ATHENA as to date largest randomized European KTx study confirmed good efficacy and event rates within international standards for all 3 groups. There were no unexpected safety events for this patient population. Of note, there were no differences in reported wound healing, no differences in proteinuria but less leukopenia and fewer infections with EVR-based regimens.

CITATION INFORMATION: Suwelack B., Sommerer C., Dragun D., Witzke O., Hugo C., Kamar N., Merville P., Hauser A., Schenker P., Junge M., Nashan B., Thaiss F. The ATHENA Study: 12 Months Safety and Efficacy Data from Everolimus Combined with Tacrolimus or Cyclosporine Compared to a Standard Tacrolimus-Mycophenolate Regimen in De Novo Kidney Transplant Patients Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Suwelack B, Sommerer C, Dragun D, Witzke O, Hugo C, Kamar N, Merville P, Hauser A, Schenker P, Junge M, Nashan B, Thaiss F. The ATHENA Study: 12 Months Safety and Efficacy Data from Everolimus Combined with Tacrolimus or Cyclosporine Compared to a Standard Tacrolimus-Mycophenolate Regimen in De Novo Kidney Transplant Patients [abstract]. https://atcmeetingabstracts.com/abstract/the-athena-study-12-months-safety-and-efficacy-data-from-everolimus-combined-with-tacrolimus-or-cyclosporine-compared-to-a-standard-tacrolimus-mycophenolate-regimen-in-de-novo-kidney-transplant-patie/. Accessed March 1, 2021.

« Back to 2018 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Enhanced Recovery after Surgery Protocols in Kidney Transplantation: Time to Change Practice?
  • Efficacy of Filgrastim in Solid Organ Transplant Recipients
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • #16789 (not found)
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.